oncology

Catalan doctor revolutionised molecular mechanism understanding, saving countless lives

Vall d’Hebron Oncology Institute helps prove efficacy of personalized treatment for BRCA gene mutation carriers

Head of oncology at Vall d'Hebron hospital will take part in worldwide Grand Challenge project

VHIO find how some tumoral cells go into hiding and emerge later to cause the disease

Vall d’Hebron Institute of Oncology presents study at ASCO meeting in Chicago

Catalonia has established a reputation as a global centre of scientific excellence, pioneering research and innovative ideas. This corner of Europe, with just 0.1% of the world’s population, accounts for nearly 1% of global scientific production. The Catalan Research system, formed of 12 internationally esteemed universities, over 60 research centres, 15 world class hospitals, and almost 9,000 innovative companies, attests to the Catalonia's ambitions in science. This territory is also a magnet of international funding: with 1.5% of Europe’s population, it receives 2.2% of European competitive funds and 3.5% of European Research Council (ERC) grants. There can be no doubt that Catalonia is now a benchmark in Southern Europe, producing frontier research and punching considerably above its weight in terms of scientific contribution.  It is attracting worldwide talent and projects, and many consider it to be fast becoming the Palo Alto of biomedical research.

The Catalan Institute of Oncology (ICO) and Roche pharmaceutical company have signed an agreement stating that the Catalan public institute will pay for treatments against cancer depending on clinical results adapted to each specific patient. For now, the agreement provides that Roche will supply two drugs against the most common cancers, mostly breast and colon. According to the agreement, the probabilities of success will be thoroughly examined and if they meet the requirements, the Catalan Government will fully pay for the treatment. If not, Roche will assume the costs progressively according to the degree of success.

Doctor Joan Massagué has been appointed Scientific Director of the Sloan-Kettering Institute in New York , the world’s leading cancer research centre, which is part of the Memorial Sloan-Kettering Cancer Centre. The Catalan scientist has been chosen by an international expert committee and will take office on the 1^st of January 2014. The President and CEO of the Memorial Sloan-Kettering, Craig B. Thomson, said that Massagué had been given the job for his “exemplarity as a scientist” and because he is an “international leader” in the study of metastasis and factors regulating cell growth. This announcement follows last year’s appointment of another Catalan Doctor, Josep Baselga, as the Physician-in-Chief of the Memorial Sloan-Kettering Cancer Centre. Both Baselga and Massagué will continue to combine their responsibilities in New York with their research in Barcelona.

The Catalan Institute of Oncology (ICO) has introduced a world pioneering technique which allows four out of five patients who cannot undergo surgery to survive the illness. This technique causes less after-effects than the traditional radiotherapy. Furthermore, statistics show that with the regular treatment, two thirds of these patients die. However, Ferran Gadea, the Head of the Radiotherapy and Oncology Service, says that the best option to cure a lung cancer is still to undergo the operation when possible.

Researchers from the Catalan Institute of Oncology have led the largest international study on breast cance4r and nutrition. The 8-year study has been based on 335,062 women between 35 and 70 years old. It has involved 23 centres in 10 European countries and it has been published in the ‘International Journal of Cancer’. The study concludes that the Mediterranean diet can reduce the risk of breast cancer by 6% among women in general and 7% in the case of post-menopausal patients.

A research group led by Catalan doctor Joaquim Bellmunt at the Hospital del Mar has shown in a study how important the time between two chemotherapy treatments is in increasing the curing rates of bladder cancer. The study was published by the journal ‘European Urology’ and has encouraged the researchers to develop new drugs for treating this type of tumour.

The New York-based centre is considered the world’s best hospital in the fight against cancer. Dr. Baselga will direct a team of 834 doctors attending more than 123,000 patients per year. The Catalan doctor is currently Chief of the Division of Hematology/Oncology at Massachusetts General Hospital (MGH), Associate Director of the MGH Cancer Center, and Scientific Director of the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona. Furthermore, Dr. Baselga holds a Chair of Medicine at the Universitat Autònoma de Barcelona (UAB). The Catalan doctor will combine his new job in New York, which will start on January 1st, with his position in Barcelona’s centre.

The centre received the ‘Gold Level Award’ from the Global Network for Tobacco Health Care Services, thanks to its fight against the effects of smoking. The jury emphasised the training given to both hospital workers and patients in order to give up smoking and the achievement of a strict non-smoking area in this health centre’s facilities. Only ten hospitals around the world have this distinction, among them another Catalan institution: Sant Joan de Déu Hospital in Manresa, in Central Catalonia.